Date: 2016-01-25
Type of information: Company acquisition
Acquired company: Q-Biologicals (Belgium)
Acquiring company: Amatsigroup (France)
Amount: undisclosed
Terms:
- • On January 25, 2016, Amatsigroup, a leading French provider of services for the development of human and veterinary pharmaceutical products, announced the acquisition of Q-Biologicals, a Belgian company that provides a comprehensive range of biologics process development and biomanufacturing services, from research to clinical phase, for customers in the biopharmaceutical industry.
Details:
- Founded in 2011, Q-Biologicals is a spin-off from the Flemish Institute of Biotechnology (VIB) and the University of Ghent (UGent). It provides a full range of process development and biomanufacturing services, specializing in biologicals used in therapeutics, vaccines and diagnostics, such as recombinant proteins, antibodies, viruses and living cells. Supported by a mix of private and public investors (VIB, Fund+, PMV, management).
- The company has its own state-of-the-art cGMP facilities and is cGMP certified (Eudra 1857). It has 20 employees for a turnover of 4 million euros in 2015. Since its foundation, Q-Biologicals has successfully delivered on almost 75 R&D projects and several clinical batch cGMP1 manufacturing projects.
- As part of its growth and international expansion strategy, Amatsigroup intends to use this acquisition as a platform to expand its services in the biological segment.
- With this new acquisition, Amatsigroup now has an integrated innovative offering for the development of new biologics through the AmatsiQBiologicals (Bioprocess – Biomanufacturing), AmatsiSEPS (Formulation Development), and AmatsiDBi (Sterile Manufacturing) facilities. Amatsigroup is now one of the few players in this sector to have a complete offering to conduct development of new biological molecules.
Related: Technology - Services
Is general: Yes
